​

Funding Round

Series B - Werewolf Therapeutics

Series B - Werewolf Therapeutics

Investment Firm

Overview

Werewolf Therapeutics operates as an oncology biotherapeutics company.

Announced Date

Jan 07, 2021

Closed on Date

Jan 07, 2021

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

RA Capital Management

RA Capital Management

RA Capital Management is a convertible_note and debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.

Participant Investors

11

Investor Name
Participant InvestorRA Capital Management
Participant InvestorLongwood Fund
Participant InvestorMPM Capital
Participant InvestorTaiho Ventures
Participant InvestorDeerfield

Round Details and Background

Werewolf Therapeutics raised $72000000 on 2021-01-07 in Series B

Werewolf Therapeutics operates as an oncology biotherapeutics company.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Nov 20, 2019
Series A - Werewolf Therapeutics
6-56.2M
Jan 07, 2021
Series B - Werewolf Therapeutics
13-72.0M
May 10, 2022
Post-IPO Secondary - Werewolf Therapeutics
-50.0M

Recent Activity

There is no recent news or activity for this profile.